secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0001104659-23-100234
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix submits SPA request to FDA for OTX-TKI pivotal trial in wet AMD
--------------------------------------------------------------------------------

- Submitted SPA request for first of two planned pivotal trials of OTX-TKI for wet AMD.
- Trial designed as superiority comparing single OTX-TKI implant vs single aflibercept injection.
- Approximately 300 treatment-naïve wet AMD subjects to be enrolled.
- Trial to be prospective, multi-center, randomized, parallel-group, mostly at U.S. sites.
- Company believes protocol aligns with prior FDA discussions and draft guidelines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923100234/0001104659-23-100234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923100234/tm2326026d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-100234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer